IRIS
CORREALE, MICHELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 1.943
NA - Nord America 1.419
AS - Asia 869
SA - Sud America 63
AF - Africa 4
Continente sconosciuto - Info sul continente non disponibili 3
OC - Oceania 1
Totale 4.302
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.401
IE - Irlanda 642
SE - Svezia 363
CN - Cina 319
SG - Singapore 298
UA - Ucraina 272
RU - Federazione Russa 208
HK - Hong Kong 147
IT - Italia 139
DE - Germania 92
AT - Austria 61
BR - Brasile 55
IN - India 50
FI - Finlandia 49
CZ - Repubblica Ceca 41
TR - Turchia 31
GB - Regno Unito 25
FR - Francia 20
CA - Canada 14
NL - Olanda 8
BE - Belgio 6
LT - Lituania 5
PE - Perù 4
AR - Argentina 3
MX - Messico 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BD - Bangladesh 2
BG - Bulgaria 2
EG - Egitto 2
ES - Italia 2
EU - Europa 2
IR - Iran 2
JO - Giordania 2
JP - Giappone 2
MA - Marocco 2
NP - Nepal 2
TH - Thailandia 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
AU - Australia 1
BO - Bolivia 1
CR - Costa Rica 1
DK - Danimarca 1
EE - Estonia 1
HR - Croazia 1
IQ - Iraq 1
KH - Cambogia 1
LA - Repubblica Popolare Democratica del Laos 1
MD - Moldavia 1
PH - Filippine 1
PK - Pakistan 1
PL - Polonia 1
RO - Romania 1
RS - Serbia 1
TM - Turkmenistan 1
TW - Taiwan 1
UZ - Uzbekistan 1
Totale 4.302
Salva come PNG Salva come JPEG
Città #
Dublin 642
Nyköping 233
Chandler 187
Jacksonville 170
Ashburn 165
Hong Kong 146
Singapore 123
Santa Clara 97
Dearborn 72
Nanjing 61
Princeton 61
Vienna 57
New York 47
Wilmington 45
Munich 44
Beijing 41
Helsinki 36
Seattle 29
Brno 28
Boardman 27
Los Angeles 27
Falkenstein 22
Nanchang 22
Pune 22
San Mateo 17
Moscow 16
Rome 16
Guangzhou 15
Tianjin 15
Des Moines 14
Olomouc 13
Assago 12
Jiaxing 11
London 11
Shenyang 11
Shanghai 10
Foggia 9
Nuremberg 9
Toronto 9
Changsha 8
Hangzhou 8
Jinan 8
Renton 8
Washington 8
Kunming 7
Lund 7
Palermo 7
Stevenage 7
Woodbridge 7
Ann Arbor 6
Brussels 6
Frankfurt am Main 6
Gesualdo 6
Hebei 6
Shenzhen 6
Acerra 5
Bari 5
Ningbo 5
Wuhan 5
Belo Horizonte 4
Changchun 4
Lanzhou 4
Messina 4
Norwalk 4
Ottawa 4
Parma 4
Philadelphia 4
San Severo 4
Amsterdam 3
Apricena 3
Bisceglie 3
Borås 3
Chongqing 3
Fuzhou 3
Hefei 3
Lima 3
Martina Franca 3
Redwood City 3
Stimigliano 3
São Paulo 3
Taglio Di Po 3
Zhengzhou 3
Amman 2
Augusta 2
Baku 2
Dongyang 2
Espoo 2
Hanover 2
Hilden 2
Kolkata 2
Manduria 2
Manfredonia 2
Mexico City 2
Milan 2
Naples 2
New Delhi 2
Orange 2
Osasco 2
Qingdao 2
Rimini 2
Totale 2.837
Salva come PNG Salva come JPEG
Nome #
Alcohol-induced cardiac disease 109
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 95
EXPRESS: Don't stop at first glance; pulmonary artery angiosarcoma mimicking chronic thromboembolic pulmonary hypertension 95
Cardiopulmonary exercise test predicts right heart catheterization 91
"PAFIYAMA" syndrome; further evidence on a novel clinical entity 89
Tissue Doppler Imaging predicts central sleep apnea in patients with chronic heart failure: data from the Daunia Registry 87
Inferior ST-Elevation Acute Myocardial Infarction or an Inferior-Lead Brugada-like Electrocardiogram Pattern Associated With the Use of Pregabalin and Quetiapine? 86
Typical Takotsubo syndrome and McConnell's phenomenon: What else lies beneath? 85
Chronic thromboembolic pulmonary hypertension. 84
Late onset of coronary vasospasm after administration of methyl-ergometrine for gynecologic bleeding. 83
Angiotensin-converting enzyme inhibitors, angiotensin II receptors antagonists, beta-blockers and ivabradine as supportive therapy in pulmonary hypertension: Drug safety and tolerability 83
Delirium in heart failure 81
Tako-Tsubo cardiomyopathy in a teen girl with pheochromocytoma. 80
Recurrent Tako-Tsubo cardiomyopathy apparently induced by opposite triggers 76
Liver disease and heart failure: Back and forth 75
Direct oral anti-coagulants compared to vitamin-K antagonists in cardioversion of atrial fibrillation: an updated meta-analysis 74
Macitentan Use in a Neurofibromatosis Type 1 Patient With Pulmonary Hypertension and External Jugular Phlebectasia 74
Direct oral anticoagulants versus standard triple therapy in atrial fibrillation and PCI: meta-analysis 73
Biomarkers in cardiorenal syndrome 71
Redefining biomarkers in heart failure 70
COMPASS vs PEGASUS approach in a comparative budget impact analysis 70
Tako-Tsubo cardiomyopathy recurrence in an elderly woman firstly diagnosed with acute myocardial infarction: How many cold cases to be reclassified? 69
Malignancies and outcome in Takotsubo syndrome: a meta-analysis study on cancer and stress cardiomyopathy 69
Fenofibrate and Dyslipidemia: Still a Place in Therapy? 68
Influence of Heart Rate on Left and Right Ventricular Longitudinal Strain in Patients with Chronic Heart Failure 68
Brain Natriuretic Peptide Biomarkers in Current Clinical and Therapeutic Scenarios of Heart Failure 65
HIV-associated pulmonary arterial hypertension: from bedside to the future 64
"ischemic" ST elevation in a woman with left ventricular hypertrophy 64
Liver disease and heart failure: an uptodate 64
SAT0325 Nailfold capillaroscopic changes in patients with idiopathic and systemic sclerosis-related pulmonary arterial ipertension 62
Advanced heart failure: non-pharmacological approach 62
Tako-Tsubo cardiomyopathy or allergic acute coronary syndrome: that is the question. 61
Novel AKAP9 mutation and long QT syndrome in a patient with torsades des pointes 61
Cardiac contractility modulation in left ventricular systolic dysfunction: trick or treat? 61
Echocardiographic score for prediction of pulmonary hypertension at catheterization: The Daunia Heart Failure Registry 58
Hospitalization cost reduction with sacubitril-valsartan implementation in a cohort of patients from the Daunia Heart Failure Registry 55
New Targets in Heart Failure Drug Therapy 55
Switch to SGLT2 Inhibitors and Improved Endothelial Function in Diabetic Patients with Chronic Heart Failure 55
Drug-Induced Pulmonary Arterial Hypertension: Mechanisms and Clinical Management 54
Gastrointestinal bleeding and coagulation disorders in a patient with left-ventricular assist device 53
Sacubitril/valsartan improves right ventricular function in a real-life population of patients with chronic heart failure: The Daunia Heart Failure Registry 53
The thromboembolism in COVID-19: the unsolved problem 53
Remodelling is inversely proportional to left ventricular dimensions in a real-life population of patients with chronic heart failure after therapy with sacubitril/valsartan 53
Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: Where do we stand? 52
Predictors of right ventricular function improvement with sacubitril/valsartan in a real-life population of patients with chronic heart failure 51
Pharmacological Anti-Remodelling Effects of Disease-Modifying Drugs in Heart Failure with Reduced Ejection Fraction 50
Switch to direct anticoagulants and improved endothelial function in patients with chronic heart failure and atrial fibrillation 50
Predictors of clinical improvement with sacubitril/valsartan in a real world population with chronic heart failure 50
ABCB1 SNP rs4148738 modulation of apixaban interindividual variability 50
The Evolving Phenotypes of Cardiovascular Disease during COVID-19 Pandemic 50
Ventilatory power, a cardiopulmonary exercise testing parameter for the prediction of pulmonary hypertension at right heart catheterization 49
Chronic thromboembolic pulmonary hypertension mimicking coronary artery disease 49
Disease-modifier Drugs in Patients with Advanced Heart Failure: How to Optimize Their Use? 48
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 48
Direct oral anticoagulants more effective than low-molecular-weight heparin for venous thrombo-embolism in cancer: an updated meta-analysis of randomized trials 47
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 47
Delirium in heart failure 45
Infection, atherothrombosis and thromboembolism beyond the COVID-19 disease: what similar in physiopathology and researches 44
Lower Major Bleeding Rates with Direct Oral Anticoagulants in Catheter Ablation of Atrial Fibrillation: an Updated Meta-analysis of Randomized Controlled Studies 42
Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone 42
Effects of Sacubitril/Valsartan on the Renal Resistance Index 41
Meta-analysis study on direct oral anticoagulants vs warfarin therapy in atrial fibrillation and PCI: Dual or triple approach? 36
Risk Reduction and Hemodynamics with Initial Combination Therapy in Pulmonary Arterial Hypertension 32
Flow Mediated Dilation in Systemic Sclerosis: Association with clinical findings, capillaroscopic patterns and endothelial circulating markers 30
LEAP Virtual Visit Assessment (VIVA): A structured protocol for virtual visits for patients with heart failure 27
Vascular and metabolic effects of SGLT2i and GLP-1 in heart failure patients 27
Optimization of Drug Therapy for Heart Failure With Reduced Ejection Fraction Based on Gender 26
Left Atrial Functional Remodeling in Patients with Chronic Heart Failure Treated with Sacubitril/Valsartan 25
Sacubitril/Valsartan in Heart Failure with Reduced Ejection Fraction: Real-World Experience from Italy (the REAL.IT Study) 24
Atrial paced rhythm and heart rate-dependent worsening of left atrial and ventricular function 24
Does the Measurement of Ejection Fraction Still Make Sense in the HFpEF Framework? What Recent Trials Suggest 23
Switch to Gliflozins and Biventricular Function Improvement in Patients with Chronic Heart Failure and Diabetes Mellitus 22
SGLT2 Inhibitors: Statins or ACE-Inhibitors of the 21st Century? 21
Arrhythmic Risk Stratification among Patients with Hypertrophic Cardiomyopathy 20
Relationship between the strain measures of left atrial function and heart failure worsening 20
Sacubitril/valsartan reduces indications for arrhythmic primary prevention in heart failure with reduced ejection fraction: insights from DISCOVER-ARNI, a multicenter Italian register 19
Improvement in Left and Right Ventricular Function after Introduction of SGLT2 Inhibitors in Heart Failure Outpatients with Reduced Ejection Fraction 19
Short-term anti-remodeling effects of gliflozins in diabetic patients with heart failure and reduced ejection fraction: an explainable artificial intelligence approach 18
Benefit from sacubitril/valsartan is associated with hemodynamic improvement in heart failure with reduced ejection fraction: An echocardiographic study 18
The Role of Congestion Biomarkers in Heart Failure with Reduced Ejection Fraction 17
Relevance of comorbidities on initial combination therapy in pulmonary arterial hypertension 17
Novelties in the pharmacological approaches for chronic heart failure: new drugs and cardiovascular targets 16
Combined peripheral and central ultrasound for the diagnosis of PAH-SSc patients 15
Deformation Imaging by Strain in Chronic Heart Failure Over Sacubitril-Valsartan: A Multicenter Echocardiographic Registry 15
Rationale and design of the Biventricular Evaluation of Gliflozins effects In chroNic Heart Failure: BEGIN-HF study 15
Introduction of SGLT2 Inhibitors and Variations in Other Disease-Modifying Drugs in Heart Failure Patients: A Single-Centre Real-World Experience 15
Alcohol consumption and subclinical and clinical coronary heart disease: New insight into potential causal mechanisms 14
Efficacy of new medical therapies in patients with heart failure, reduced ejection fraction, and chronic kidney disease already receiving neurohormonal inhibitors: a network meta-analysis 14
The paradox of pulmonary arterial hypertension in Italy in the COVID-19 era: is risk of disease progression around the corner? 14
Effect of sacubitril/valsartan on cardiac remodeling compared with other renin–angiotensin system inhibitors: a difference-in-difference analysis of propensity-score matched samples 13
Echocardiographically defined haemodynamic categorization predicts prognosis in ambulatory heart failure patients treated with sacubitril/valsartan 13
SGLT2 Inhibitors Introduction and Changes of the Other Disease Modifiers’ Drugs in Heart Failure Patients: A Single Center Real World Experience 13
Imaging Modality to Guide Left Atrial Appendage Closure: Current Status and Future Perspectives 12
Impact of Frailty on Outcome of Older Patients With Non-ST Elevation Acute Myocardial Infarction Who Undergo Percutaneous Coronary Intervention 11
Endothelial Function Correlates With Pulmonary Pressures in Subjects With Clinically Suspected Pulmonary Hypertension 10
HOW TO IMPROVE ADHERENCE TO ESC HF GUIDELINES THE PONTE (PDTA FOR INTEGRATED FOLLOW-UP TERRITORY HOSPITAL OF THE PATIENT WITH CARDIAC HEART FAILURE) PROJECT 10
Pleiotropic Effects of Direct Oral Anticoagulants in Chronic Heart Failure and Atrial Fibrillation: Machine Learning Analysis 9
Left ventricular reverse remodeling after combined ARNI and SGLT2 therapy in heart failure patients with reduced or mildly reduced ejection fraction 9
Biomarker profiles that differentiate type-1 and type 2 myocardial infarction 9
Endothelial Function in Pulmonary Arterial Hypertension: From Bench to Bedside 9
Totale 4.614
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.085
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.085
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020111 0 0 0 0 0 0 0 0 50 14 44 3
2020/2021371 50 7 42 12 43 3 51 54 52 56 1 0
2021/2022412 17 2 11 3 70 14 11 38 49 86 6 105
2022/20231.331 117 69 83 38 31 104 2 86 702 10 40 49
2023/2024585 57 18 39 19 79 124 13 94 1 11 14 116
2024/20251.195 88 18 28 77 50 243 159 115 417 0 0 0
Totale 4.660